Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 13/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 13/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | ALB | P02768 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28851780 | 0.91 | HPGD (0.55) | HPGDFOLH1HDAC1HDAC2HDAC3 | |
| SCHEMBL1870930 | 0.89 | HPGD (0.39) | HPGDFOLH1HDAC1HDAC2HDAC3 | |
| SCHEMBL10340280 | 0.87 | HDAC1 (0.47) | HDAC1HDAC2HDAC4HDAC6ALDH1A1 | |
| SCHEMBL3490799 | 0.86 | ALDH1A1 (0.46) | HDAC1HDAC2HDAC4HDAC6ALDH1A1 | |
| SCHEMBL1752117 | 0.84 | ALDH1A1 (0.48) | HPGDHDAC1HDAC2ALDH1A1PKM | |
| Hydrogen Sulfide SCHEMBL20305480 | 0.83 | ALDH1A1 (0.47) | HPGDHDAC1HDAC2ALDH1A1PKM | |
| SCHEMBL29380577 | 0.82 | HPGD (0.57) | HPGDHDAC1HDAC2HDAC3HDAC4 | |
| SCHEMBL155342 | 0.82 | HPGD (0.57) | HPGDHDAC1HDAC2HDAC3HDAC4 | |
| SCHEMBL19444563 | 0.81 | HPGD (0.56) | HPGDHDAC1HDAC2HDAC3HDAC4 | |
| SCHEMBL24274154 | 0.79 | HPGD (0.43) | HPGDHDAC1HDAC2HDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 365 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3765188-B1 | SURFACE FUNCTIONALISED MATERIALS FOR SAMPLING BIOLOGICAL MOLECULES | JONES PAUL ANTONIO (GB) | 2025-04-16 | — | — | EP | claimed |
| EP-1853634-B1 | ACTIVATED SIALIC ACID DERIVATIVES FOR PROTEIN DERIVATISATION AND CONJUGATION | LIPOXEN TECHNOLOGIES LTD (GB) | 2016-08-10 | — | — | EP | claimed |
| EP-1776389-B1 | SIALIC ACID DERIVATIVES | LIPOXEN TECHNOLOGIES LTD (GB) | 2016-06-29 | — | — | EP | claimed |
| EP-2478049-B1 | A POLYMER SUPPORT | UNIV CAPE TOWN (ZA) | 2015-02-25 | — | — | EP | claimed |
| US-20120135891-A1 | METHODS AND DEVICES FOR EARLY DETECTION OF CANCER CELLS AND TYPES THROUGH MICROMECHANICAL INTERACTIONS | STIHARU, ION | 2012-05-31 | — | — | US | claimed |
| US-20080318242-A1 | METHODS AND DEVICES FOR EARLY DETECTION OF CANCER CELLS AND TYPES THROUGH MICROMECHANICAL INTERACTIONS | STIHARU, ION (CA) | 2008-12-25 | — | — | US | claimed |
| EP-0941738-B1 | Antigenic conjugates of conserved lipooligosaccharides of gram negative bacteria | WYETH CORP (US) | 2005-05-11 | — | — | EP | claimed |
| US-20040052804-A1 | Antigenic conjugates of conserved lipopolysaccharides of gram negative bacteria | WYETH HOLDINGS CORPORATION | 2004-03-18 | — | — | US | claimed |
| US-6645503-B1 | Eliciting a cross reactive immune response against heterologous strains of the gram negative bacteria; vaccines; comprises the inner core and lipid A portions of the lipopolysaccharide | WYETH HOLDINGS CORPORATION | 2003-11-11 | — | — | US | claimed |
| US-20030129642-A1 | Novel compositions and methods for inhibiting light-induced inactivation of biological reagents | BIOSITE DIAGNOSTICS, INC. | 2003-07-10 | — | — | US | claimed |
| EP-0701448-B1 | AMPLIFICATION OF THE VITAMIN B 12 UPTAKE SYSTEM USING POLYMERS | BIOTECH AUSTRALIA PTY LTD (AU) | 2002-08-14 | — | — | EP | claimed |
| US-6316266-B1 | PROVIDING MASS SPECTROMETRY SAMPLE PRESENTATION METAL SURFACE; CONTACTING COMPLEX WITH SURFACE TO FORM A SURFACE-BOUND COMPLEX; CONTACTING BIOMOLECULE WITH COMPLEX; APPLYING MATRIX ASSISTED LASER DESORPTION/IONIZATION MATRIX; DETERMINATION | ARIZONA STATE UNIVERSITY BOARD OF REGENTS | 2001-11-13 | — | — | US | claimed |
| US-6004770-A | MASS SPECTROMETRY SAMPLE PRESENTATION APPARATUSES DERIVATIZED WITH COMPLEXES INCLUDING AT LEAST ONE MOLECULE WHICH MODIFIES A BIOMOLECULE | ARIZONA STATE UNIVERSITY BOARD OF REGENTS (US) | 1999-12-21 | — | — | US | claimed |
| EP-0941738-A1 | Antigenic conjugates of conserved lipopolysaccharides of gram negative bacteria | American Cyanamid Company (US) | 1999-09-15 | — | — | EP | claimed |
| EP-0701448-A4 | AMPLIFICATION OF THE VITAMIN B 12? UPTAKE SYSTEM USING POLYMERS | BIOTECH AUSTRALIA PTY LTD (AU) | 1997-01-02 | — | — | EP | claimed |
| EP-0701448-A1 | AMPLIFICATION OF THE VITAMIN B 12? UPTAKE SYSTEM USING POLYMERS | BIOTECH AUSTRALIA PTY. LIMITED (AU) | 1996-03-20 | — | — | EP | claimed |
| US-5449720-A | Amplification of the VB12 uptake system using polymers | BIOTECH AUSTRALIA PTY LIMITED (AU) | 1995-09-12 | — | — | US | claimed |
| WO-1994027641-A1 | AMPLIFICATION OF THE VITAMIN B12 UPTAKE SYSTEM USING POLYMERS | BIOTECH AUSTRALIA PTY. LIMITED (AU) | 1994-12-08 | — | — | WO | claimed |
| US-12630651-B2 | Anti-sclerostin constructs and uses thereof | ANGITIA INCORPORATED LIMITED (US) | 2026-05-19 | — | — | US | disclosed |
| WO-1994027641-A1 | AMPLIFICATION OF THE VITAMIN B12 UPTAKE SYSTEM USING POLYMERS | BIOTECH AUSTRALIA PTY. LIMITED (AU) | 1994-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630651-B2 | Anti-sclerostin constructs and uses thereof | SOST, VSIR, VSIG8 | HPGD 4230/4885FOLH1 1264/4885HDAC1 4640/4885 |
| US-20040052804-A1 | Antigenic conjugates of conserved lipopolysaccharides of gram negative bacteria | LY96, DDOST, LRBA | HPGD 2010/4885FOLH1 501/4885HDAC1 2949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.